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Background: The aim of this study was to investigate the mechanisms underlying the therapeutic effect of Uygur
medicine KJA on UC in a rat model.
Methods: UC was induced in Wistar rats by application of 2, 4-dinitrochlorobenzene and acetic acid and were then
treated with three different doses of KJA, and normal saline as control. After treatment for 20 days, the gene
expression profile of colonic tissue was analyzed by microarray and verified by quantitative real-time RT-PCR.
Results: Animals treated with the three different doses of KJA were compared with normal saline controls, wherein
microarray analysis identified 1991, 2163, and 1677 differentially expressed genes respectively, of which 444 genes
were raised and 670 genes were decrease spliced together in the three doses tested. The KEGG pathway analyses
found commonly raised genes related to several different biological functions. Interesting genes included TRL2, IL-1β,
TGF-β1, and NF-κB were confirmed by quantitative PCR.
Conclusions: The therapeutic effect of KJA on UC is likely explained by specific effects on the expression of genes,
which are the effector molecules known to be involved in the development of UC. Further studies on differentially
expressed genes will help explain the mechanism of action of Uygur medicine KJA.
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Ulcerative colitis (UC) is a chronic non-specific inflam-
mation and ulceration of the digestive tract, involving
mainly mucous membranes of the large intestine with
serious complications and often recurrent attacks lasting
several months to years [1]. UC is common in the rec-
tum, sigmoid flexure and left colon. The incidence of
UC is in the range of approximately 0.5 – 24.5/100,000
of the population depending upon the economic status
of the country [2, 3]. It is classified as one of the refrac-
tory diseases by WHO [4].
Although there has been marked progress in under-
standing the pathogenesis of the disease over the last* Correspondence: zjp_1215@163.com
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unless otherwise stated.several years, the main causes of UC remain unclear. En-
vironmental factors, immunologic factors, and genetic
susceptibility seem to partly contribute to the develop-
ment of chronic inflammation in the gut [5–9]. Cur-
rently, there is no curative treatment available for UC.
Various drugs that are used systemically and/or topically
to induce and maintain remission include aminosali
cylates, glucocorticosteroids and immunomodulators
[10–16]. Surgical therapy is an option for patients with
toxic colonitis who depend on prolonged hormonal ther-
apy. However, surgical therapy requires resecting the en-
tire intestine and inosculating ileum and anus; however,
about 40% of patients appear with acute inflammation of
the bursa bag [17]. Patients without proper treatment
may develop colon cancer [18, 19]. Therefore, novel and
effective therapeutics exhibiting reduced toxicity are ur-
gently needed for treating UC.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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broadly categorized as alternative medicine. Some of the
drugs commonly prescribed in Uygur Medicine have
shown promising therapeutic effects in UC. Uygur Medi-
cine Xipayi Kui Jie’an (KJA) prescription from the uygur
medicine approach called “Xipayi gingiva protective so-
lution”, in accordance with the Ministry of Health of the
People’s Republic of China Pharmaceutical Standards –
Uighur Medicine [20] from the 1998 edition, is com-
posed of gallic acid. Previously we have reported that
KJA is curative in a rat model of UC by colon tissue
morphology and pathological changes. In this model, we
observed reduced inflammation, and evaluated the scope
of curative effect after treatment [21–23]. To explore the
potential mechanisms of the therapeutic effect of KJA
on UC, we used gene chip technology and examined the
effect of KJA on gene expression profiles of diseased in-
testinal tissues from UC rats.
Methods
Experimental animals
Specific pathogen-free (SPF) adult male Wistar rats (220-
250 g) were provided by the Experimental Animal Center
of Xinjiang Medical University. They were housed in a
controlled environment (temperature 24–25°C, humidity
70%–75%) and were fed on a normal laboratory diet. Rats
were rested for at least 1 week before use. All experiments
were conducted according to the guidelines of the local
ethics committee at Xinjiang Medical University (Permit
Number: IACUC-20121122011).
Establishment of UC rat model
Experimental animal grouping consisted of 109 Wistar
rats that were stochastically divided into the following
groups: normal group (7 rats); an ulcerative colitis model
group (21 rats with 5 deaths); a physiological saline/
negative control group (21 rats, 10 deaths); the Xipayi
Kui Jie’an large dose intervention group (19 rats, 7
deaths); the medium dose intervention group (20 rats, 5
deaths); and the small dose intervention group (21 rats,
5 deaths). We created a rat model of UC using 2.4-dini-
trochlorobenzene (DNCB) composite in acetic acid. The
rats were administered 0.25 mL of DNCB acetone liquid
(DNCB 2.0 g:acetone 100 mL) solution on depilated
areas of the back and neck daily for 14 days. The DNCB,
acetone, and ethanoic acid used in this experiment were
domestically produced and analytically pure. Following
application of the DNCB on day 14, the rats were fasted
(with free access to water drinking) for 24 h. On day 15,
0.25 mL of a 0.1% DNCB ethyl alcohol solution was
injected into the rat colon via a 3 mm-diameter catheter
that was inserted 8 cm past the anus. On day 16, the
same procedure was used to inject 2 mL of 6% ethanoic
acid. The solution was allowed to have an effect for 15 s,before 5 mL of physiologic saline solution was used to
flush the area. Subsequently, rats were fed for 7 days and
stool characters, dietetics, hair condition and activity
were monitored daily. Observations showed that that the
rats gradually produced typical symptoms of UC, thus
confirming that the model of UC was successfully estab-
lished. The normal group rats fed without any processing.Source of drugs
Xipayi Kui Jie’an Enema (Preparation Standard of Medical
Institutions Formulated by the Food and Drug Adminis-
tration of Xinjiang Uygur Autonomous Region ZZJ-0001-
2013) is composed of garlic (liquid herbal extract, 50 mL/
bag includes 2 g of crude drug), and was provided by
Xinjiang Cicon Habo Uyghur Medicine Co., Ltd. (Urumqi,
China). The common therapeutic dose of KJA for humans
is 23 mg/kg/d. The equivalent dose in rats is 150 mg/kg/d;
this was used as the medium dose, while 75 mg/kg/d and
300 mg/kg/d were used as the low and high doses,
respectively.
[Preparation method]: The medicinal material nutgall
was taken and crushed into coarse powders. Water 10
times the amount was added for 8 h of overnight soak-
ing. Then after the material was decocted for 3 times
with 1 h each time, the decoctions were combined and
pressured with the plate and frame (0.3 MPa). After that,
the combined decoction was filtrated with a speed of 5
tons/h (200 mesh filter cloth) and the filtrate was added
with 0.2% sodium benzoate which was dissolved by stir-
ring to prepare 1000 ml liquid. Finally, the enema was
obtained after repackaging.
[Identification]: 1 ml of the product was taken and
added with water to 10 ml. Then ethyl acetate was
added and extracted 2 times after vibration with 5 ml
each time. The ethyl acetate liquid was combined and
dried. And the residual was added with 2 ml methanol
for dissolution and used as the test solution. Gallic
acid was additionally taken as the control and added
with methyl alcohol to be the solution with 1 mg
Gallic acid in 1 ml solution as the control. According
to the test of thin layer chromatography (TLC) (ap-
pendix VI B of Chinese pharmacopoeia, 2010 edition),
5 μl control solution and 2 μl test solution were
absorbed and respectively dripped on the same thin
layer plate made up of silica G with sodium carboxy-
methyl cellulose as the binder. And after they were de-
veloped with chloroform-ethyl acetate-formic acid
(6:4:1) as the developer, they were taken out, dried in
the air and sprayed with 1% ferric chloride ethanol
solution. In the chromatogram of the test solution,
spots were shown with the same color at the corre-
sponding positions of the chromatography of the
control solution.
Table 1 Sequences of primers used in quantitative real-time
reverse transcription polymerase chain reaction
Gene symbol Primer Sequences Length
TLR2 Forward:5′-CTTACAGGACACTGGGGGAAC-3′ 134bp
Reverse:5′-AAGTTCGTTGAGAGAGGTCAGC-3′
NF-κB Forward:5′-TGATGACATACTCCCACAAG-3′ 145 bp
Reverse:5′-CAATATCCCCAGACCTAAC-3′
IL-1β Forward:5′-GACCTGTTCTTTGAGGCTGAC-3′, 578 bp
Reverse:5′-TCCATCTTCTTCTTTGGGTATTGTT-3′
TGF-β1 Forward:5′-GAGAGCCCTGGATACCAACTA-3′ 173 bp
Reverse:5′-CTGGTGTGTCCAGGCTCCAAATGT-3′
β-actin Forward:5′-AACTCCATCATGAAGTGTGA-3′ 248 bp
Reverse:5′-ACTCCTGCTTGCTGATCCAC-3′
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The rats with treatment were clystered using a suitable
tube inserted into the colondaily with normal saline
(22.5 mL/kg) as a negative control, and with low, medium
and high doses of KJA, should choose liquid paraffin
wax was used as a lubricant. After 20 days of treatment,
the animals were fasted overnight before being sacrificed
by administering an overdose of ether . The distal colon
with a length of 5-8 cm was removed for extraction of
total RNA. After removing the connective and adipose tis-
sues, the colon was cut open along the mesenteric edge
and rinsed from the inside gently with cold RNase-free sa-
line. The colon tissue samples were stored at -80°C before
isolation of total RNA.
Transcriptomic analysis
The total RNA was extracted from the colon tissues by
the Trizol (Invitrogen, Gaithersburg, MD, USA) one-step
method. After enrichment of RNA by isopropyl alcohol
precipitation, total RNA was column purified by using a
NucleoSpin® RNA clean-up kit (MACHEREY-NAGEL,
Germany). The concentration and purity of total RNA
were determined by a spectrophotometer, and the qual-
ity assessment was conducted by the integrity of 28S and
18S rRNA. We used the rat genome 70-mer oligonucleo-
tide microarray version 3.05, representing about 22, 012
genes and 27, 044 transcripts (for detailed information
refer to http://www.Operon.com), from the CapitalBio
Corporation (Beijing, China) [24, 25] for monitoring
changes in gene expression profiles.
Microarray imaging and data analysis
Arrays were scanned with a confocal LuxScan™ scanner
and the images were analyzed using LuxScan™ 3.0 software
(both from CapitalBio). For individual channel data ex-
traction, faint spots with intensities below 400 units after
background subtraction in both channels (Cy3 and Cy5)
were removed and a space- and intensity-dependent
normalization that was based on a LOWESS program was
applied [26]. The significance of differentially expressed
genes was determined using Significance Analysis of Mi-
croarrays (version 3.02). We set the criteria for differen-
tially expressed genes as the ratio of two channels for the
same gene as ≥ 2 or ≤ 0.5, P < 0.05, after allowing for qual-
ity control analysis and normalization of the data.
Bioinformatics analysis of differentially expressed genes
Functional analysis of gene expression was performed
using CapitalBio Corporation Bio-molecular function an-
notation system (MAS system http://www.capitalbio.com)
to annotate the differentially expressed genes and permit
statistical analysis of the pathway enrichment. The Capital-
Bio Molecule Annotation System (MAS; version 4.0),
KEGG, and GenMAPP were used for pathway analysis(http://bioinfo.capitalbio.com/mas) [27]. For each pathway,
genes with known rat orthologues were compared with
sets of significant genes from SAM to define the effects of
the corresponding pathway.
Confirmation of microarray results with quantitative real-
time RT- PCR
A Crystal core® EvaGreen fluorescence quantitative two-
step RT-PCR universal kit (CapitalBio) was used to verify
the differentially expressed genes that were identified by
microarray analysis. Primer sequences (see Table 1) for
amplification of TLR2, IL-1β,NF-κB, and TGF-β1 were
designed based on the sequences published in GeneBank
using the software program Primer Premier Express
v5.0, and synthesized by the Takara Company (Dalian
,china). The PCR amplification was conducted at 95°C
for 15 min, followed by 40 cycles of 94°C for 5 s, 58°C
for 15 s, and 72°C for 10 s. The changes in target genes
were determined using the 2−ΔΔCt method [28].
Statistical analysis
Data analysis was performed using SPSS software v13.0.
Values were reported as mean ± SD. ANOVA followed
by Student’s t-test was used for multiple comparisons of
the data. Statistical significance was set at an alpha value
of p < 0.05.
Results
The effect of KJA on the gene expression profile in
intestinal mucosa in rats with UC
To understand the underlying mechanism of KJA to UC
rats, we established a rat UC model and examined the
effect of KJA treatment on the gene expression profile in
local colon tissues by cDNA microarray analysis. Com-
pared to the three different doses (high, medium, and
low) of KJA with normal saline control rats, the micro-
array analysis identified 1991, 2163, and 1677 differen-
tially expressed genes in the rat respectively, of which
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spliced together in the three doses tested . Genes that
showed significant changes in expression were mapped
to the KEGG pathways (Tables 2, and 3). Commonly
raised genes were related to oxidative phosphorylation,
disease, and metabolism reactions. Cut genes related to
cell adhesion molecules (CAMs), immune responses,
metabolism, and signaling pathways. This suggested the
involvement of complicated mechanisms in the effect of
KJA to UC
Real-time fluorescence quantitative RT - PCR analysis of
differentially expressed genes
After identification of differentially expressed genes by
KJA treatment by microarray analysis, we performed
quantitative RT-PCR for selected genes in the intestinal
samples from UC rats treated with KJA to confirm the
microarray data. For this, we concentrated on evaluation
of TRL2, IL-1β, TGF-β1, and NF-κB, since these genes
were implicated in the development of UC [29, 30]. We
evaluated the expression of these genes using quantitative
real-time RT-PCR from total RNA samples isolated from
3 rats representing each group. Our results demonstratedTable 2 Significantly Changed Genes (different doses common ra
Pathway Count p-Value
Cell adhesion molecules (CAMs) 13 9.35E-12
Natural killer cell mediated cytotoxicity 12 8.04E-11
Focal adhesion 13 1.61E-10
Complement and coagulation cascades 9 3.42E-10
ECM-receptor interaction 8 1.55E-08
Leukocyte transendothelial migration 9 4.12E-08
Primary immunodeficiency 6 6.53E-08
Arachidonic acid metabolism 6 1.61E-06
Systemic lupus erythematosus 8 2.56E-06
Antigen processing and presentation 7 2.92E-06
Regulation of actin cytoskeleton 9 5.00E-06
T cell receptor signaling pathway 6 6.53E-05
Hematopoietic cell lineage 5 1.02E-04
Axon guidance 6 1.25E-04
Small cell lung cancer 5 2.92E-04
Citrate cycle (TCA cycle) 3 7.92E-04that expression of these genes were increased significantly
in intestinal mucosa of UC rats as compared with that
expressed in the intestinal mucosa of normal rats (Fig. 1).
Treatment of UC rats with KJA for 20 days differentially
reduced the expression of IL-1β, TGF-β1, TLR2 and NF-
κB in the low dose group as compared with the normal sa-
line control group. These results were consistent with the
microarray data (Fig. 2). In conclusion, our studies with
quantitative PCR analysis of selected genes identified with
microarray analysis further verified differentially expressed
genes in rats with UC as compared with that found in nor-
mal rats. Our observations also demonstrated the specific
effect of KJA treatment on the expression of these genes
in rats with UC. Thus, we conclude that KJA exerts its
therapeutic effects by differentially regulating expression
of several different key molecules associated with the de-
velopment of UC.
Discussion
Ulcerative colitis is a chronic inflammatory bowel dis-
ease that predominantly involves the large intestine with
limited therapeutic options, with the notable exception


























Table 3 Significantly Changed Genes (different doses cut together) Mapped to KEGG Pathways
Pathway Count p-Value q-Value Gene
Oxidative phosphorylation 24 4.93E-28 5.32E-26 Atp5b;Cox4i1;Ndufb5;Cox6c;Cox5a;LOC685596;Cox6c1;Atp5a1;LOC683884;Ndufab1;
Cox5b;Cox6b1;RGD1559626;Atp5h;Ndufa5;Uqcrfs1;Ndufb8;Ndufa3;
LOC684509;Atp5f1;LOC692052;LOC679739;Uqcrq;Ndufs5




Parkinson's disease 24 8.34E-27 3.00E-25 Atp5b;Cox4i1;Ndufb5;Cox6c;Cox5a;LOC685596;Cox6c1;Atp5a1;LOC683884;Ndufab1;
Cox5b;Cox6b1;RGD1559626;Atp5h;Ndufa5;Uqcrfs1;
Ndufb8;Ndufa3;LOC684509;Atp5f1;LOC692052;LOC679739;Uqcrq;Ndufs5
PPAR signaling pathway 9 1.49E-10 1.46E-09 Fabp2;Hmgcs2;Ehhadh;Acadm;Cpt1a;Pdpk1;Cpt2;Lpl;Angptl4
Valine, leucine and
isoleucine degradation
7 3.94E-09 3.54E-08 Hmgcs2;Ehhadh;Acadm;Acaa2;Pccb;Acaa2;Hadha;Bcat1
Fatty acid metabolism 6 7.74E-08 5.57E-07 Ehhadh;Acadm;Acaa2;Cpt1a;Acaa2;Hadha;Cpt2
Arginine and proline
metabolism
5 7.00E-07 4.45E-06 Ckmt1;Ckb;Eprs;Rars;P4ha3
Drug metabolism - other
enzymes
5 5.56E-06 2.73E-05 Ugt1a3;Ugt1a6;Ugt1a1;Ces2;Upp1
Fatty acid elongation in
mitochondria
3 1.69E-05 7.95E-05 Acaa2;Acaa2;Hadha;Ppt1
Propanoate metabolism 4 2.12E-05 9.55E-05 Ehhadh;Acadm;Pccb;Hadha
Drug metabolism -
cytochrome P450
5 2.89E-05 1.20E-04 Ugt1a3;Ugt1a6;Ugt1a1;Gstm5;Fmo1
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showed induction of UC in rats following the application
of acetic acid combined with DNCB, a commonly used
animal model of UC [31], and studied the effects of ap-
plying Uygur medicine KJA in rats with UC. The
changes in gene expression patterns were seen at all
three doses of KJA, and these results suggest that appli-
cation of KJA in UC rats induced significant changes in
genes expression, and provided a potential mechanism
for the therapeutic effect of KJA on UC. Treatment of
UC rats with three different concentrations of KJA forFig. 1 Quantitative real-time RT-PCR analysis of the selected gene expressio
UC rats treated with normal saline (UC + normal saline) and UC rats that w
expression levels for TLR2, IL-1β, TGF-β1 and NF-κB were quantified using
3 rats per group are shown. UC rats vs. normal rats: * P < 0.05,and ** P < 020 days changed the expression profile of these genes in
the intestinal tissues as compared with UC rats treated
with normal saline. We concluded all changes gene sim-
ultaneously in all three doses of KJA. The differentially
expressed genes represent several different functional
groups, and are mainly involved in oxidative phosphoryl-
ation, cell metabolism, cell signaling, and inflammation
and immunity. The increase in expression of genes in-
volved in “cell adhesion molecules (CAMs)” and “regula-
tion of actin cytoskeleton” indicates that KJA may play a
significant role in control of both the actin cytoskeletonn in rat colon tissue. The total RNA samples from normal rats, UC rats,
ere treated with low dose KJA (UC + KJA) were extracted and mRNA
β-actin as an internal control for normalization. Means and SD from
.01; UC + KJA vs. UC + normal saline: #P < 0.05,and ##P < 0.01
Fig. 2 The effect of KJA on TLR2, IL-1β and TGF-β1 expression in colon tissues from rats. Representative microarray images of cDNA samples derived
from different groups of rats are shown (n = 3). The arrows indicate the corresponding gene spots for TLR2, IL-1β and TGF-β1. Red color denotes an
increase of gene expression, whereas green colored spots indicates a decrease
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sion of genes involved in “natural killer cell mediated
cytotoxicity” and “T cell receptor signaling pathway”
functions suggested that an autoimmune response is in-
volved in the treatment of UC with KJA. On the other
hand, the decrease in the expression of genes involved in
“oxidative phosphorylation”, “Alzheimer’s disease” and
“Parkinson’s disease” indicates that KJA contributes to
the risk of mitochondrial DNA variants. A significant de-
crease in expression of genes involved in “valine, leucine
and isoleucine degradation”, “fatty acid metabolism”, “ar-
ginine and proline metabolism”, “propanoate metabol-
ism” and increased expression of genes involved in the
“citrate cycle” indicate that KJA decreases protein and
lipid metabolism and increases the energy status of the
citrate cycle, thereby regulating metabolism during
chronic inflammation.
Our studies identified the gene expression patterns
that were associated with immunity and inflammatory
reactions, including TLR2, NF-κB, IL-1β and TGF-β1,
with quantitative PCR analysis in the normal rat group,
UC rat group, normal saline control group, and KJA
small dose group respectively.
TLR2 is a member of the Toll-like receptor (TLR)
family, and TLRs play fundamental roles in pathogen
recognition and activation of innate immunity. Thevarious TLRs exhibit different patterns of expression.
TLR2 is expressed most abundantly in peripheral blood
leukocytes, and mediates host immune responses to
Gram-positive bacteria and yeast via stimulation of NF-
κB [32–34]. In normal intestine, TLR2 is expressed
mainly in lamina propria mononuclear cells and intes-
tinal epithelial cells at low levels. Increased expression of
TLR2 in patients with UC is caused mainly by increased
leukocyte infiltration in the intestinal mucosa, which has
been associated with the development of UC [35]. IL-1β
is also shown to mediate the pathogenesis of UC [30].
The most significant and relevant properties of IL-1β are
the initiation of cyclooxygenase type 2, inducible nitric
oxide synthase and phospholipase A2, which are pro-
duced by various cell types [36]. TGF-β1 belongs to
transforming growth factor beta (TGF-β) family of cyto-
kines, which are multifunctional peptides that regulate
proliferation, differentiation, adhesion, migration, and
functional activation of immune cells. This gene is fre-
quently upregulated in tumor cells, and mutations in the
TGF-β1 gene results in human disease [37–39]. TGF- β1
is elevated in the local inflammatory tissue in the intes-
tinal mucosa of UC patients and is associated with de-
velopment of UC [40, 41].
In recent years, herbal therapy or traditional Chinese
medicine for the treatment of patients with UC have
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cinal enemas can effectively inhibit regional mucosal in-
flammatory factors and improve disorders associated
with immunity [42, 43]. Our results showed that expres-
sion of TLR2, NF-κB, IL-1β and TGF-β1 were increased
in the intestinal mucosa of UC rats with quantitative
PCR analysis. Treatment of UC rats with KJA signifi-
cantly reduced the expression of NF-κB, IL-1β and TGF-
β1in the intestinal mucosa as compared with UC rats
treated with normal saline. The expression of KJA on
TLR2 was also reduced, although its effect was less
dramatic.
Based on our experimental data, we assume that the
DNCB combined acetic acid induced pathogenesis of rat
UC, led to the destruction of the intestinal mucosa, initiat-
ing abnormal changes in the immune system of the intes-
tinal mucosa, and thereby disrupted the balance between
local immunity and intestinal flora symbiosis. The dis-
order between promoting inflammation and suppression
of inflammatory factors may lead to an imbalance of im-
mune regulation, causing the abnormal immune response
of the intestinal mucosa, which eventually leads to damage
of the intestinal mucosa. Application of KJA reverses this
imbalanced local immune reaction and may also initiate
the recuperation of local intestinal epithelial cells and
healing of uncreative lesions. KJA can significantly im-
prove diarrhea, stool and weight loss and other symptoms
in rats with UC [23]. Pathological findings showed that
KJA can reduce inflammatory cell infiltration, promote
ulcer healing with curative effects on UC [22, 23], and
thus support the changes in the critical genes we describe
here.
The possible mechanism of Uygur medicine KJA to
treat ulcerative colitis is probably mediated by reducing
the expression of inflammation promoting factors, thus
providing potential molecular mechanisms for the cura-
tive effect of KJA on UC. Future studies aimed at cell
specific analysis of the differentially regulated genes in
the colon tissue before and after treatment with KJA
may lead to improved understanding of the therapeutic
effect of KJA on UC.
Conclusions
Using the crystal core® 27 rat genome oligonucleotide
array, we detected changes in the gene expression pro-
files from different doses of KJA in a rat model of UC.
Through analysis of gene chip data mapped to the
KEGG pathways, the effect of KJA in UC rats might be
associated with oxidative phosphorylation, disease, me-
tabolism reactions, CAMs, immune responses, and sig-
naling pathways. The quantitative real-time RT-PCR
results of TLR2, IL-1β, TGF-β1 and NF-κB expression,
verified consistently with the microarray data. On com-
parison of the Uygur medicine KJA intervention groupwith the physiological saline negative control group,
Uygur medicine KJA can successfully treat UC rats by
dampening the expression of TLR2, IL-1β, TGF-β1 and
NF-κB. Further studies on differentially expressed genes
will help explain the mechanism of action of Uygur
medicine KJA.
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